Articles tagged with: Myeloma Canada
NewsFlash »
Eighth Canadian Province Approves Revlimid Funding – Revlimid (lenalidomide) in combination with dexamethasone (Decadron) is now funded and accessible in Manitoba, Canada for multiple myeloma patients who have been previously treated. Only two provinces, Nova Scotia and Prince Edward Island, deny access to myeloma patients who do not have private insurance. Myeloma Canada, an organization dedicated to supporting myeloma patients, will continue campaigning for universal coverage of Revlimid. For more information, please see the Myeloma Canada press release.
Astex And MMRC Begin Phase 2 Study Of AT7519 For Myeloma – Astex Therapeutics has launched a Phase 2 clinical trial, funded by the Multiple Myeloma Research Consortium (MMRC), of AT7519 for relapsed or refractory multiple myeloma patients. AT7519 is a cyclin-dependent kinase inhibitor that prevents the growth and spread of myeloma cells by interfering with cell division. Previous trials have shown it has significant anti-tumor effect. AT7519 will be tested alone and in combination with Velcade (bortezomib). For more information, see the MMRC press release.
IMF Will Hold Myeloma Patient And Family Seminar – The International Myeloma Foundation (IMF) will hold an educational program for multiple myeloma patients and their families on August 27 and August 28 in Universal City, CA. Doctors in the myeloma field will answer questions and cover topics such as managing side effects, current standard treatments, and on-going clinical trials. The cost for the seminar is $60 per person. For more information or to register, please see the IMF website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
European Commission Grants Marketing Authorization For Mozobil – On August 5, the European Commission granted marketing authorization for Mozobil in the European Union. Access to Mozobil will allow multiple myeloma patients who require a stem cell transplant a new option. The drug is used in combination with a granulocyte-colony stimulating factor which stimulates bone marrow, and together they increase the mobilization of stem cells to the bloodstream for collection and use in stem cell transplants. Mozobil was approved in December 2008 in the United States. For more information, please see the Genzyme press release.
Sausalito Music Fan’s Bike Ride To Saratoga To Raise Money For MMRF – Cathy Gellis will be riding her bike from Sausalito, CA, to Saratoga, CA, to raise funds for the Multiple Myeloma Research Foundation (MMRF) and to see Huey Lewis and the News on August 15. She is riding in memory of Ron Stallings, a band member of the band who passed away earlier this year after being diagnosed with multiple myeloma. For more information or to make a donation, please visit Cathy’s page on the MMRF Web site.
Prairie Pedal For Myeloma – The Prairie Pedal for Myeloma blog is written by Shane Saunderson. It follows his bike ride from Calgary to Toronto to raise funds for Myeloma Canada and the Molly and David Bloom Chair in Multiple Myeloma Research. His goal is to ride 3500 km in 35 days and to raise $35,000. Shane began his ride on August 1. To follow the blog or make a donation, please visit the Prairie Pedal for Myeloma Canada Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
News»
In November 2008, Myeloma Canada, which works in close affiliation with the International Myeloma Foundation, commissioned a national survey called Time to Life on cancer and treatment in Canada.
The survey found that multiple myeloma is still relatively unknown to the general population. An estimated 6,000 Canadians live with the condition. Only 15 percent of Canadians surveyed were able to identify multiple myeloma as a blood cancer. One third thought it was a type of skin cancer, and 36 percent admitted to being unfamiliar with the disease.
The survey was conducted by …